India launched Production Linked Incentive (PLI) schemes to become a manufacturing powerhouse. But four years later, a recent report shows they've missed almost two-thirds of their targets, with manufacturing's share in GDP declining instead of growing.
Let’s break it down 🧵👇
Manufacturing has a unique impact on the economy. Research shows that manufacturing jobs create 2.3 times more indirect employment than services. A 10% rise in manufacturing cuts poverty 2.1 times faster than a similar rise in services.
A 1% increase in manufacturing’s GDP share can boost economic growth by 0.5–0.7% in low and middle-income countries.
Without a strong manufacturing base, India depends on imports, especially from China. This weakens our economy and puts constant pressure on our trade balance.
In November 2020, the government launched PLI under ‘Atmanirbhar Bharat’ to fix these issues. It covered 14 sectors with ₹1.97 lakh crore in incentives. The plan was to drive $500 billion in production, create jobs, and push manufacturing’s share to 25% of GDP by 2025.
The reality has been very different. As of October 2024, firms in the PLI program have produced just $151.93 billion worth of goods—only 37% of the target. Incentive payouts have been slow, with only $1.73 billion disbursed so far, less than 8% of the total allocation.
Instead of growing, manufacturing’s share of the economy has shrunk, falling from 14.1% to 12.9% since PLI was launched.
Not everything has failed, though. Two sectors—electronics manufacturing services and pharmaceuticals—have done well. Mobile phone production jumped 63% to $49 billion last year, and Apple now manufactures its latest iPhones in India. Pharma exports have nearly doubled in a decade to $28 billion.
But that’s just two out of fourteen sectors. Others are nowhere close to hitting their targets. Earlier, there was talk of expanding PLI to more industries. Now, that plan is off the table. The government has hinted that if existing sectors can’t meet their targets, the program could be scaled back.
Why has PLI struggled? First, overambitious targets. Many companies set sky-high expectations they can't meet. The solar industry is a perfect example—eight out of twelve firms are on track to miss targets, including big names like Reliance, Adani, and JSW. In steel, fourteen of fifty-eight approved projects have been withdrawn for lack of progress.
Delays have been another issue. Many firms only got selected for PLI incentives in 2022, two years behind schedule. That lost momentum has been costly, especially in capital-intensive sectors like semiconductors and advanced batteries, where full-scale production hasn’t even begun.
Complex compliance requirements have made things worse. High investment thresholds, rigid sales targets, and strict domestic value-addition rules have created endless compliance headaches. Some investors would rather hold back than deal with the complexity.
PLI was meant to boost India’s manufacturing, but most of it hasn’t worked as planned. Maybe the targets were too high, maybe the process was too slow. What’s clear is that India needs a stronger manufacturing base. If PLI is the answer, it has to change because, in its current form, it’s falling short.
We cover this and one more interesting story in today's Daily Brief in detail. You can watch the episode on YouTube, read on Substack, or listen on Spotify, Apple Podcasts, or wherever you get your podcasts. All links here: thedailybrief.zerodha.com/p/weight-loss-…
• • •
Missing some Tweet in this thread? You can try to
force a refresh
The prices of rice across the world are falling dramatically. Thai white rice just fell to $405/ton from $669 in January. The reason? India lifted its export restrictions. As the world's largest rice exporter, India's policies directly impact food prices for billions.
Here's what happened:🧵👇
This isn't just about prices - it's about global food security. In many South/Southeast Asian and African countries, rice provides up to two-thirds of daily calories. When India restricts exports, millions face higher costs for their most essential food.
This wasn't always the case. In the 1960s-70s, India was importing rice. The Green Revolution changed everything, and by the 2000s, we became an export powerhouse.
Wind power in India stagnated at 0% growth last year, while solar surged 22%. A random fluctuation? Maybe not. Zooming out, the data tells a deeper story.🧵👇
Solar power in India has been pulling ahead of wind for years. From 2019–2023, solar grew up to 28.2% annually, while wind managed just 2.8%–6.7%. By early 2025, solar capacity surpassed 100 GW—more than double wind’s ~49 GW. The gap keeps widening.
Why is solar power outpacing wind?
1⃣ First, cost matters. Solar has become incredibly cheap thanks to China flooding markets with panels. Wind turbines remain complex and expensive, making them harder to sell despite their benefits.
SEBI just wrapped up one of the most bizarre stock fraud cases in years. And at the centre of it? Not a stockbroker or a backroom operator, but Hemant Ghai, a former CNBC Awaaz anchor millions trusted for market advice. 🧵👇
SEBI’s final order in the Hemant Ghai case bans him, his wife, and his mother from the stock market for five years. It also orders them to return ₹6 crore in illegal profits and holds MAS Consultancy & Motilal Oswal responsible for lapses.
Ghai hosted "Stock 20-20," one of India's most-watched morning shows where he recommended 10 stocks daily before the market opened. His picks would regularly spike in price minutes after the show aired as viewers rushed to buy them.
Weight loss medication Mounjaro has finally launched in India. At Rs. 3,500-4,375 per weekly dose, it's expensive - potentially Rs. 2 lakh annually. But this drug does far more than help with weight loss.
Here's what you need to know.🧵👇
Mounjaro is similar to Ozempic but reportedly even more effective for weight loss. While pricey now, competition will likely increase after 2026 when Novo Nordisk's patent on Semaglutide expires.
These medications work with GLP-1, a hormone our bodies naturally produce. The breakthrough came from studying the venom of the Gila monster lizard, which contains a GLP-1-like substance that's much more stable.
Here’s an interesting headline we came across recently: Audi to cut 7,500 jobs in Germany to become more efficient. Now, on the face of it, this might look like a normal restructuring that a company might do to improve their numbers. But it marks a broader trend: Germany’s famous automotive industry — famed for making cars that you dream of owning someday — is in deep trouble.
Let us start by giving you some context.🧵👇
You see, the world’s big three auto manufacturers — Volkswagen (which owns Audi), BMW, and Mercedes — all hail from Germany. This industry is extremely important for Germany’s economy. It accounts for a huge portion of Germany’s GDP — roughly 5% — and more than one-tenth of its exports.
The industry is also a big employer. Not only do automotive manufacturers employ hundreds of thousands of people on their own rolls, but they also sustain a massive supply chain, indirectly creating millions of more jobs. In all, 5.3 million German jobs are dependent on the automotive sector. For context, that is one in every seven of the country’s jobs.
At its peak, Germany was producing over 6 million cars annually, with exports flooding into markets worldwide, from the U.S. to China. Chances are, every really rich person you know owns one of those cars. For years, everything was going right. Profits were pouring in, the brands were expanding, and demand was strong.
China presents a fascinating economic paradox today: a nation simultaneously experiencing its worst growth slump in decades alongside a booming tech sector. This "tale of two Chinas" has major implications for global markets and geopolitics.🧵👇
On paper, China's economy looks concerning. Official figures show 5% real GDP growth in 2024, but nominal growth was just 4.2% – the lowest in decades outside the pandemic. Independent analysts like Rhodium Group suggest actual growth may be even lower at 2.4-2.8%.
The gap between China and the US is widening, not narrowing. China's GDP has fallen from 77% of US GDP in 2021 to 64% last year. Pre-COVID forecasts expected China to overtake the US within a decade. Current projections push that to the 2040s, if ever.